Literature DB >> 24788530

Immunohistochemical analysis of expressions of RB1, CDK4, HSP90, cPLA2G4A, and CHMP2B is helpful in distinction between myxofibrosarcoma and myxoid liposarcoma.

Tao Wang1, Mark A Goodman2, Richard L McGough2, Kurt R Weiss2, Uma N M Rao2.   

Abstract

The role and diagnostic efficacy of gene and protein products RB1, CDK4, CHMP2B, HSP90, and cPLA2G4A, all previously shown to be involved in tumor genesis and cell proliferation, were examined by immunohistochemical techniques in 32 cases of myxofibrosarcomas and 29 myxoid liposarcomas (all diagnosis had been confirmed by fluorescence in situ hybridization). HSP90 demonstrated strong nuclear and cytoplasmic positivity in all myxoid liposarcoma cases, while only 4 myxofibrosarcomas showed scattered HSP90 positivity. All but 4 cases of myxofibrosarcoma displayed strong positivity for cPLA2G4A, while only 2 myxoid liposarcoma cases were cPLA2G4A positive and both were CHMP2B negative. Overexpression of both cPLA2G4A and CHMP2B also suggested higher tumor grade. In conclusion, HSP90 and cPLA2G4A immunohistochemical stains are useful markers to distinguish myxofibrosarcoma from myxoid liposarcoma.
© The Author(s) 2014.

Entities:  

Keywords:  CDK4; CHMP2B; CPLA2G4A; HSP90; RB1; myxofibrosarcoma; myxoid liposarcoma

Mesh:

Substances:

Year:  2014        PMID: 24788530     DOI: 10.1177/1066896914532539

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  3 in total

1.  CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest.

Authors:  Ashleigh M Francis; Angela Alexander; Yanna Liu; Smruthi Vijayaraghavan; Kwang Hui Low; Dong Yang; Tuyen Bui; Neeta Somaiah; Vinod Ravi; Khandan Keyomarsi; Kelly K Hunt
Journal:  Mol Cancer Ther       Date:  2017-06-15       Impact factor: 6.261

2.  Cell cycle and apoptosis regulatory proteins, proliferative markers, cell signaling molecules, CD209, and decorin immunoreactivity in low-grade myxofibrosarcoma and myxoma.

Authors:  Justin M M Cates; Vincent A Memoli; Raul S Gonzalez
Journal:  Virchows Arch       Date:  2015-05-05       Impact factor: 4.064

Review 3.  Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.

Authors:  Jocelyn Y Hsu; Nathan D Seligson; John L Hays; Wayne O Miles; James L Chen
Journal:  JCO Precis Oncol       Date:  2022-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.